Glenmark Pharmaceuticals Limited (GLENMARK.NS)
Company Info
Highlights
₹408.58B
-₹36.04
₹97.08B
₹48.51B
₹20.92B
₹769.90 - ₹1,830.95
₹1,741.46
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of ₹10,000 in Glenmark Pharmaceuticals Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Glenmark Pharmaceuticals Limited had a return of -12.76% year-to-date (YTD) and 69.66% in the last 12 months. Over the past 10 years, Glenmark Pharmaceuticals Limited had an annualized return of 6.77%, while the S&P 500 had an annualized return of 11.21%, indicating that Glenmark Pharmaceuticals Limited did not perform as well as the benchmark.
GLENMARK.NS
-12.76%
-6.21%
-5.49%
69.66%
34.36%
6.77%
^GSPC (Benchmark)
2.90%
3.70%
10.94%
22.18%
12.41%
11.21%
Monthly Returns
The table below presents the monthly returns of GLENMARK.NS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -10.12% | -12.76% | |||||||||||
| 2024 | 6.54% | 2.00% | 3.26% | 10.88% | 10.38% | 5.38% | 19.38% | 17.72% | -2.69% | 0.88% | -10.05% | 5.48% | 89.46% |
| 2023 | -9.60% | 11.90% | 8.10% | 21.21% | 5.90% | 13.60% | 16.99% | -3.02% | 11.55% | -12.21% | 4.19% | 8.97% | 101.15% |
| 2022 | -7.92% | -7.53% | -1.74% | -0.33% | -10.55% | -2.12% | -1.30% | -2.38% | 5.70% | 3.35% | 7.09% | -1.47% | -18.91% |
| 2021 | -3.89% | -1.77% | -0.11% | 24.26% | 2.81% | 9.76% | -6.49% | -13.00% | -3.32% | -1.04% | 3.67% | 0.81% | 7.56% |
| 2020 | -10.73% | -10.25% | -26.26% | 64.63% | 5.01% | 26.68% | 0.36% | 4.01% | 3.40% | -1.33% | -0.97% | 4.55% | 42.66% |
| 2019 | -5.78% | -8.66% | 8.22% | -1.71% | -14.12% | -18.73% | -3.81% | -9.06% | -15.72% | -2.64% | 6.08% | 3.55% | -49.61% |
| 2018 | 1.76% | -9.99% | -3.49% | 8.57% | -5.69% | 8.61% | -0.17% | 13.98% | -5.08% | -1.59% | 5.58% | 5.79% | 16.72% |
| 2017 | 0.47% | 3.24% | -8.97% | 6.39% | -28.60% | -0.69% | 9.87% | -12.55% | -1.16% | 3.17% | -8.72% | 5.32% | -32.91% |
| 2016 | -15.34% | -5.41% | 7.87% | 4.31% | 2.62% | -5.99% | 7.87% | -2.48% | 10.05% | 1.46% | -6.56% | 1.59% | -3.07% |
| 2015 | -6.86% | 10.45% | -1.10% | 13.62% | -2.02% | 14.47% | 0.87% | 12.94% | -7.35% | -5.73% | -0.99% | -6.24% | 19.78% |
| 2014 | 4.59% | 2.14% | -0.25% | 7.82% | -9.95% | 3.21% | 15.70% | 9.17% | 0.04% | 0.22% | 14.10% | -6.14% | 44.82% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 90, GLENMARK.NS is among the top 10% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Glenmark Pharmaceuticals Limited (GLENMARK.NS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Glenmark Pharmaceuticals Limited provided a 0.18% dividend yield over the last twelve months, with an annual payout of ₹2.50 per share. The company has been increasing its dividends for 15 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | ₹2.50 | ₹2.50 | ₹2.50 | ₹2.50 | ₹2.50 | ₹2.50 | ₹2.00 | ₹2.00 | ₹2.00 | ₹2.00 | ₹2.00 | ₹2.00 |
Dividend yield | 0.18% | 0.16% | 0.29% | 0.59% | 0.47% | 0.51% | 0.58% | 0.29% | 0.34% | 0.22% | 0.22% | 0.26% |
Monthly Dividends
The table displays the monthly dividend distributions for Glenmark Pharmaceuticals Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₹0.00 | ₹0.00 | ₹0.00 | ||||||||||
| 2024 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.50 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.50 |
| 2023 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.50 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.50 |
| 2022 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.50 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.50 |
| 2021 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.50 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.50 |
| 2020 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.50 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.50 |
| 2019 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.00 |
| 2018 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.00 |
| 2017 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.00 |
| 2016 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.00 |
| 2015 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.00 |
| 2014 | ₹2.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹0.00 | ₹2.00 |
Dividend Yield & Payout
Dividend Yield
Payout Ratio
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Glenmark Pharmaceuticals Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Glenmark Pharmaceuticals Limited was 84.22%, occurring on Mar 23, 2020. Recovery took 1043 trading sessions.
The current Glenmark Pharmaceuticals Limited drawdown is 22.42%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -84.22% | Aug 21, 2015 | 1132 | Mar 23, 2020 | 1043 | Jun 5, 2024 | 2175 |
| -83.39% | Feb 11, 2000 | 380 | Aug 17, 2001 | 544 | Oct 23, 2003 | 924 |
| -82.91% | Jun 16, 2008 | 156 | Feb 4, 2009 | 1375 | Aug 13, 2014 | 1531 |
| -78.9% | Oct 25, 2003 | 21 | Nov 21, 2003 | 248 | Nov 17, 2004 | 269 |
| -40.76% | May 15, 2006 | 23 | Jun 14, 2006 | 95 | Oct 27, 2006 | 118 |
Volatility
Volatility Chart
The current Glenmark Pharmaceuticals Limited volatility is 10.53%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Glenmark Pharmaceuticals Limited.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |